Johnson & Johnson told a judge its $9 billion proposal to settle baby powder cancer claims in bankruptcy court is the only ...

Johnson & Johnson faces a critical test on Tuesday over its $10 billion proposal to end litigation alleging that its baby ...

A Johnson & Johnson unit working to resolve massive cancer litigation in bankruptcy court was accused by a former head of the ...

Under a settlement inked with J&J in late 2023, Samsung Bioepis and Sandoz got the all-clear to launch their Stelara biosimilar from Feb. 22, 2025. The settlement is one of many J&J has inked over ...

J&J said it is seeking a preliminary injunction for Samsung Bioepis' Stelara biosimilar over an unauthorized sublicense deal ...

J&J has announced plans to finalise a US$6.48bil global settlement through the bankruptcy of a subsidiary company, after earlier efforts were rebuffed twice by federal courts.

Opponents of the J&J proposal argue the settlement should not bind those who do not like the terms and would prefer to take their chances in court. But J&J argues that bankruptcy offers a faster ...

Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to ...

By pushing the deal through a subsidiary’s bankruptcy, J&J is trying to force women with ovarian cancer to accept lower settlement payments based on a deeply flawed vote, according to opponents.

J&J is attempting to use a subsidiary's bankruptcy ... now has votes showing a broad level of support for its settlement proposal. "We have the vote," Red River Talc's attorney Allison Brown ...